Compare BridgeBio Pharma Inc (BBIO) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Johnson Controls International PLC — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Johnson Controls International PLC trades at $155.47 (market cap $91.29B). The key difference: Johnson Controls International PLC is far larger — about 5.5× BridgeBio Pharma Inc's market cap, and Johnson Controls International PLC pays a 1.06% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | JCI | |
|---|---|---|
Market Cap | $16.61B | $91.29B |
Sector | Health | Industrials |
52-Week High | $90.17 | $154.76 |
52-Week Low | $47.29 | $103.52 |
Enterprise Value | $18.16B | $100.12B |
Dividend Yield | — | 1.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Johnson Controls International (JCI) trades at $152.21, down 1.51% on the day, but maintains a bullish technical outlook with strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with EPS of $1.42 versus $1.30 expected, and raised full-year guidance. Fundamentals show solid revenue growth and expanding net income margins, though valuation multiples like a P/E of 42.88 appear elevated. Recent news highlights strong demand for its thermal management systems, particularly in data centers.
JCI's outlook is positive, driven by operational strength and strategic positioning in high-growth markets like AI infrastructure. Investment opportunities include continued earnings beats and market share gains in energy efficiency solutions. Key risks involve high valuation sensitivity, competitive pressures, and macroeconomic factors affecting construction and industrial spending. The consensus price target of $168.25 suggests ~10% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
